



## How patients should use Increlex®

- \$\frac{1}{2}\$ Increlex should be given twice a day
- \$\frac{1}{2}\$ Increlex should be given shortly before or just after a meal
- If an Increlex dose cannot be given shortly before or just after a meal, that dose of Increlex should not be given
- Be alert for the signs and symptoms of low blood sugar levels that your doctor or nurse has advised you of. Carry a supply of sugar to take should they appear
- Use a different injection site on the skin with each dose

Rotate injection sites

☆ Abdomen

🕏 Buttock

🛠 Thigh

🛠 Upper arm

If a dose is missed, subsequent doses of Increlex should never be increased to make up for it. The next dose should be taken at the usual time

Increlex should be kept in the refrigerator but must NOT be frozen - store at 2°C - 8°C

Current Summary of Product Characteristics for Great Britain can be found at the following link: https://www.medicines.org.uk/emc/product/101145/smpc

▼Increlex is subject to additional monitoring as a condition of its marketing authorisation in Europe. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should be reported to Esteve via email at medinfo.uk@esteve.com or phone on 0330 1359 437

UK version 1 Date of preparation: Oct 2025 MHRA approval date: 18/11/2025

UK version 1 Date of preparation: Oct 2025 MHRA approval date: 18/11/2025



# The Increlex® Dosing Guide

How to use Increlex® in the treatment of severe primary IGF-1 deficiency

This leaflet is produced by Esteve

Summary of Product Characteristics information can be found at the end of the document.

UK version 1 Date of preparation: Oct 2025 MHRA approval date: 18/11/2025

#### How to use this guide

The tables on the following pages have been designed to help you calculate the appropriate dose per injection for your patient. When you have found the patient's body weight in the first column, the corresponding number under the mg/kg dose is the units per injection.

Dose (in units) per injection is calculated using the formula:

Weight (kg) x single dose (mg/kg) x 10 = units per injection

Recommended starting dosage is 0.04mg/kg twice daily by subcutaneous injection. If well tolerated **for at least a week**, dose may be increased by 0.04mg/kg increments, to the maximum of 0.12mg/kg twice daily.

Doses greater than 0.12mg/kg twice daily should not be exceeded as this may increase the risk of neoplasia.

The dose is calculated in units as Increlex is administered using an insulin syringe.

\$\frac{1}{2}\$ Dose ranges from 0.04mg/kg to 0.12mg/kg twice daily

\$\square\$ Syringe units range from 2 units to 84 units

\$\frac{1}{2}\$ The injection site should be rotated with each dose

\$\square\$\$ Increlex should always be given shortly before or just after a meal

#### Hypoglycaemia

If hypoglycaemia occurs at recommended doses, despite adequate food intake, the dose should be reduced.

### For patients weighing 5kg to 37kg

Patient's	D	ose p	er in	jectio	on (m	g/kg	) twic	e da	ily
weight (kg)	.04	.05	.06	.07	.08	.09	.10	.11	.12
5	2	3	3	4	4	5	5	6	6
6	2	3	4	4	5	5	6	7	7
7	3	4	4	5	6	6	7	8	8
8	3	4	5	6	6	7	8	9	10
9	4	5	5	6	7	8	9	10	11
10	4	5	6	7	8	9	10	11	12
11	4	6	7	8	9	10	11	12	13
12	5	6	7	8	10	11	12	13	14
13	5	7	8	9	10	12	13	14	16
14	6	7	8	10	11	13	14	15	17
15	6	8	9	11	12	14	15	17	18
16	6	8	10	11	13	14	16	18	19
17	7	9	10	12	14	15	17	19	20
18	7	9	11	13	14	16	18	20	22
19	8	10	11	13	15	17	19	21	23
20	8	10	12	14	16	18	20	22	24
21	8	11	13	15	17	19	21	23	25
22	9	11	13	15	18	20	22	24	26
23	9	12	14	16	18	21	23	25	28
24	10	12	14	17	19	22	24	26	29
25	10	13	15	18	20	23	25	28	30
26	10	13	16	18	21	23	26	29	31
27	11	14	16	19	22	24	27	30	32
28	11	14	17	20	22	25	28	31	34
29	12	15	17	20	23	26	29	32	35
30	12	15	18	21	24	27	30	33	36
31	12	16	19	22	25	28	31	34	37
32	13	16	19	22	26	29	32	35	38
33	13	17	20	23	26	30	33	36	40
34	14	17	20	24	27	31	34	37	41
35	14	18	21	25	28	32	35	39	42
36	14	18	22	25	29	32	36	40	43
37	15	19	22	26	30	33	37	41	44
									_

### For patients weighing 38kg to 70kg

Date and initiation (and the bride daily

Patient's	Do	ose p	er in	jecti	on (n	ng/kg	) twi	ce da	ily
weight (KG)	.04	.05	.06	.07	.08	.09	.10	.11	.12
38	15	19	23	27	30	34	38	42	46
39	16	20	23	27	31	35	39	43	47
40	16	20	24	28	32	36	40	44	48
41	16	21	25	29	33	37	41	45	49
42	17	21	25	29	34	38	42	46	50
43	17	22	26	30	34	39	43	47	52
44	18	22	26	31	35	40	44	48	53
45	18	23	27	32	36	41	45	50	54
46	18	23	28	32	37	41	46	51	55
47	19	24	28	33	38	42	47	52	56
48	19	24	29	34	38	43	48	53	58
49	20	25	29	34	39	44	49	54	59
50	20	25	30	35	40	45	50	55	60
51	20	26	31	36	41	46	51	56	61
52	21	26	31	36	42	47	52	57	62
53	21	27	32	37	42	48	53	58	64
54	22	27	32	38	43	49	54	59	65
55	22	28	33	39	44	50	55	61	66
56	22	28	34	39	45	50	56	62	67
57	23	29	34	40	46	51	57	63	68
58	23	29	35	41	46	52	58	64	70
59	24	30	35	41	47	53	59	65	71
60	24	30	36	42	48	54	60	66	72
61	24	31	37	43	49	55	61	67	73
62	25	31	37	43	50	56	62	68	74
63	25	32	38	44	50	57	63	69	76
64	26	32	38	45	51	58	64	70	77
65	26	33	39	46	52	59	65	72	78
66	26	33	40	46	53	59	66	73	79
67	27	34	40	47	54	60	67	74	80
68	27	34	41	48	54	61	68	75	82
69	28	35	41	48	55	62	69	76	83
70	28	35	42	49	56	63	70	77	84

# How patients should use Increlex

### Information for parents, carers and patients

Complete the patient's name and dose before giving the final sheet to your patient - it contains useful and important information about how to administer Increlex.

lame of patient:	
Pose in units:	

#### Contact information

Name	of	doctor:	

Name of nurse:

Surgery/contact phone number:

Increlex is subject to additional monitoring as a condition of its marketing authorisation in Europe. This will allow quick identification of new safety information. You can help by reporting any side effects your child gets.

Reporting of side effects If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/ yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

UK version 1 Date of preparation: Oct 2025 MHRA approval date: 18/11/2025